CCCC (C4 Therapeutics) ROCE %: -34.50% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CCCC C4 Therapeutics Inc CCCC
49 GF Score
Price $4.12
GF Value $2.05
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is C4 Therapeutics ROCE %?

C4 Therapeutics CCCC +2.50% 49 ROCE % is -34.50% as of Jun. 2026. GuruFocus rates CCCC with a GF Score™ of 49/100 and a GF Value™ of $2.05 (Significantly Overvalued). The stock has 7 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. C4 Therapeutics's annualized ROCE % for the quarter that ended in Jun. 2026 was -34.50%.

C4 Therapeutics  (NAS:CCCC) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

C4 Therapeutics ROCE % Related Terms

C4 Therapeutics ROCE % Historical Data

* Premium members only.

The historical data trend for C4 Therapeutics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

C4 Therapeutics ROCE % Chart

C4 Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial -20.14 -29.93 -36.07 -36.73 -33.15

C4 Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -42.96 -39.33 -33.33 -35.41 -34.50
CCCC
49GF Score
C4 Therapeutics Inc CCCC
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

C4 Therapeutics ROCE % Calculation

C4 Therapeutics's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-104.489/( ( (349.602 - 45.177) + (359.075 - 33.032) )/ 2 )
=-104.489/( (304.425+326.043)/ 2 )
=-104.489/315.234
=-33.15 %

C4 Therapeutics's ROCE % of for the quarter that ended in Jun. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Jun. 2026 )  (Q: Mar. 2026 )(Q: Jun. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Jun. 2026 )  (Q: Mar. 2026 )(Q: Jun. 2026 )
=-105.692/( ( (328.861 - 27.249) + (359.404 - 48.247) )/ 2 )
=-105.692/( ( 301.612 + 311.157 )/ 2 )
=-105.692/306.3845
=-34.50 %

(1) Note: The EBIT data used here is four times the quarterly (Jun. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -34.50% mean?
C4 Therapeutics (CCCC) has a ROCE % of -34.50% as of Jun. 2026.
Is C4 Therapeutics' ROCE % too high?
C4 Therapeutics' current ROCE % is -34.50%. Overall, C4 Therapeutics has a GF Score™ of 49/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does C4 Therapeutics' ROCE % compare to CMPX and AVIR?
C4 Therapeutics' ROCE % of -34.50% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. C4 Therapeutics's current ROCE % is -34.50%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is C4 Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, C4 Therapeutics (CCCC) is currently considered Significantly Overvalued. The stock's GF Value™ is $2.05, compared to a current price of $4.12 — trading 100.7% above its estimated fair value. The current ROCE % is -34.50%. C4 Therapeutics' overall GF Score™ is 49/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For C4 Therapeutics (CCCC), the current ROCE % is -34.50% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is C4 Therapeutics (CCCC) Overvalued in 2026?

Based on GuruFocus' analysis, C4 Therapeutics stock appears to be overvalued. The current stock price of $4.12 is trading 100.7% above its estimated GF Value™ of $2.05. GuruFocus considers C4 Therapeutics to be Significantly Overvalued.

Key valuation signals for CCCC:

  • ROCE %: -34.50%
  • GF Value™: $2.05 vs. price of $4.12 (100.7% above fair value)
  • GF Score™: 49/100 with 7 warning signs

No single metric tells the full story. See the CCCC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

C4 Therapeutics Business Description

Address 490 Arsenal Way, Suite 120, Watertown, MA, USA, 02472
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patient's lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. The degrader medicines of the company are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT8919, and other discovery products.
49GF Score

Get the complete analysis for CCCC

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.12
Price
$2.05
GF Value